Stock Taper 
MacroGenics, Inc. is a biopharmaceutical company developing antibody-based cancer therapies, including the approved HER2-positive breast cancer drug MARGENZA, with a pipeline targeting solid tumors, hematologic malignancies, HIV, and autoimmune di...
MacroGenics' bispecific DART® molecule targets PD-1 and CTLA-4, is in Phase 2 trials for metastatic prostate and gynecologic cancers, and is its most advanced clinical-stage candidate.
In August 2025, MacroGenics announced that its Chief Operating Officer, Eric Risser, would take over as President and CEO, succeeding Scott Koenig who had led the company for 24 years. [1, 5, 6] This transition was presented as a pivotal moment, emphasizing a strategic shift to enhance capital efficiency, optimize the product pipeline, and extend the company's cash runway, which was a key focus in subsequent investor communications. [1, 12, 17]
In a significant strategic realignment, MacroGenics announced the discontinuation of the LORIKEET Phase 2 trial for lorigerlimab in combination with docetaxel for metastatic castration-resistant prostate cancer (mCRPC). This decision followed a portfolio review and evaluation of interim data, signaling a move to reallocate resources to more promising programs within its antibody-drug conjugate (ADC) portfolio.
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 STTK | $5.77 | COMPARE |
 OVID | $2.35 | COMPARE |
 IFRX | $1.49 | COMPARE |
 WHWK | $3.48 | COMPARE |
 ZNTL | $2.50 | COMPARE |
 ORMP | $4.21 | COMPARE |
 COYA | $4.90 | COMPARE |
 CNTB | $0.91 | COMPARE |
